Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Lotus Eye Hospital & Institute's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Lotus Eye Hospital & Institute's highest Yield on Cost was 2.94. The lowest was 0.50. And the median was 0.93.
BOM:532998's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.905 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Lotus Eye Hospital & Institute (BOM:532998) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Lotus Eye Hospital & Institute 5-Year Yield-on-Cost % Related Terms
BOM:532998 vs HCA, THC, EHC: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, Lotus Eye Hospital & Institute's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lotus Eye Hospital & Institute 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Lotus Eye Hospital & Institute's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Lotus Eye Hospital & Institute's 5-Year Yield-on-Cost % falls into.
Lotus Eye Hospital & Institute 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Lotus Eye Hospital & Institute (BOM:532998) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 04, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lotus Eye Hospital & Institute and its competitors. Over the past decade, Lotus Eye Hospital & Institute's 5-Year Yield-on-Cost % has ranged from 0.50 to 2.94. According to the industry distribution chart, Lotus Eye Hospital & Institute ranks #999999 out of 280 companies in the Healthcare Providers & Services industry.
Is Lotus Eye Hospital & Institute's 5-Year Yield-on-Cost % too high?
Lotus Eye Hospital & Institute's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.50 to a high of 2.94. Based on the distribution chart, Lotus Eye Hospital & Institute ranks #999999 out of 280 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Lotus Eye Hospital & Institute has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lotus Eye Hospital & Institute's 5-Year Yield-on-Cost % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Lotus Eye Hospital & Institute ranks #999999 out of 280 companies for 5-Year Yield-on-Cost %. This places Lotus Eye Hospital & Institute in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.91. Historically, Lotus Eye Hospital & Institute's own 5-Year Yield-on-Cost % has ranged from 0.50 to 2.94 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.91, based on 280 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lotus Eye Hospital & Institute and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lotus Eye Hospital & Institute's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lotus Eye Hospital & Institute stock overvalued right now?
Based on GuruFocus' analysis, Lotus Eye Hospital & Institute (BOM:532998) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹98.44, compared to a current price of ₹110.65 — trading 12.4% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Lotus Eye Hospital & Institute's overall GF Score™ is 71/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Lotus Eye Hospital & Institute (BOM:532998), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lotus Eye Hospital & Institute (BOM:532998) Overvalued in 2026?
Based on GuruFocus' analysis, Lotus Eye Hospital & Institute stock appears to be overvalued.
The current stock price of ₹110.65 is trading 12.4% above its estimated GF Value™ of ₹98.44.
GuruFocus considers Lotus Eye Hospital & Institute to be Modestly Overvalued.
Key valuation signals for BOM:532998:
5-Year Yield-on-Cost %: 0.00
GF Value™: ₹98.44 vs. price of ₹110.65 (12.4% above fair value)
No single metric tells the full story. See the BOM:532998 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lotus Eye Hospital & Institute Ltd is an India-based eye care hospital. It is engaged in providing treatment and care for eye diseases and disorders. It offers treatment services for eye conditions like refractive error, retina and uvea, cornea, glaucoma, pediatric, orbit and oculoplasty, neuro-ophthalmology, and binocular vision. In addition, the company also operates an eye bank for functioning eye donation activities. The company mainly operates in India and generates revenue by providing medical services, pharmacy sales, contact lenses, and optical, of which the majority of the revenue is derived from providing segmmedical services.
71GF Score
Get the complete analysis for BOM:532998
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:532998 has been successfully added to your 
